MARINUS PHARMACEUTICALS, INC. On May 16, 2023, the Board of Directors (the “Board”) of Marinus Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from eight to nine members and, upon recommendation by the Nominating and Governance Committee of the Board, appointed Sarah Noonberg, M.D., Ph.D. as a member of the Board, effective immediately. Ms. Noonberg will serve as a Class II member of the Board. The term of the Class II directors will expire at the 2025 Annual Meeting of Stockholders.
Dr. Noonberg is a physician-scientist with a diverse background in translational science, clinical development, medical affairs, and corporate governance. She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization. Dr. Noonberg currently serves as the Chief Medical Officer of Metagenomi, a privately held genomics company, where she is advancing its gene editing technology platform toward the clinic.
She previously served as Chief Medical Officer of Maze Therapeutics, Nohla Therapeutics and Prothena Biosciences and prior to that, held clinical development executive leadership roles at BioMarin and at Medivation. Her industry experience is complemented by more than 10 years of experience treating patients as a hospitalist physician. Sarah currently serves on the Board of Directors at Protagonist Therapeutics and Neoleukin Therapeutics.
She trained in internal medicine at Johns Hopkins Hospital, received an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkeley, and a bachelor's degree in engineering science from Dartmouth College. Additionally, the Board appointed Ms. Noonberg to serve on the Science and Technology Committee of the Board.
